Clinical Scorecard: Meta-analysis of Documented Cases of 17α-Hydroxylase/17,20-Lyase Deficiency (17-OHD)
At a Glance
Category
Detail
Condition
17α-Hydroxylase/17,20-Lyase Deficiency (17-OHD), a rare form of congenital adrenal hyperplasia caused by CYP17A1 gene mutations
Key Mechanisms
Pathogenic variants in CYP17A1 cause defective 17α-hydroxylase/17,20-lyase enzyme activity, impairing cortisol and sex steroid synthesis and causing mineralocorticoid excess
Target Population
Patients with CYP17A1 mutations presenting with hypertension, hypokalemia, and disorders of sexual development, including both 46,XY and 46,XX individuals
Care Setting
Specialist endocrinology and genetics clinics with capacity for genetic testing and hormone assays
Key Highlights
465 unique patients analyzed from 178 studies, mean age 18.9 years, 52.5% 46,XY karyotype
Common clinical features include hypertension (57%), hypokalemia (45.4%), primary amenorrhea (38.3%), cryptorchidism (15.3%), and atypical genitalia (14.2%)
Severe variants such as p.Y329Kfs associate with hypocortisolism, combined hypokalemia and hypertension, and disordered sexual development
Guideline-Based Recommendations
Diagnosis
Consider 17-OHD in patients presenting with disordered sexual development and hypertension
Confirm diagnosis by genetic testing for CYP17A1 variants
Assess serum hormone levels including cortisol, progesterone, 11-deoxycorticosterone, and sex steroids to evaluate enzyme impairment severity
Management
Manage hypertension and hypokalemia resulting from mineralocorticoid excess
Address disorders of sexual development with multidisciplinary care including endocrinology and urology/genetics
Provide hormone replacement therapy as indicated by cortisol and sex steroid deficiencies
Monitoring & Follow-up
Regular blood pressure and serum potassium monitoring
Periodic assessment of hormone levels to guide therapy adjustments
Monitor pubertal development and sexual characteristics
Risks
Delayed diagnosis especially in phenotypic females presenting later with primary amenorrhea and hypertension
Misdiagnosis due to rarity and variable clinical presentation
Potential complications from untreated hypertension and electrolyte imbalances
Patient & Prescribing Data
Patients with genetically confirmed 17-OHD across diverse ethnic backgrounds
Severity of CYP17A1 variants correlates with clinical phenotype and guides hormone replacement and supportive therapies
Clinical Best Practices
Early genetic testing in patients with hypertension and disorders of sexual development
Use combined clinical, biochemical, and genetic data to classify severity and tailor management
Multidisciplinary approach involving endocrinologists, geneticists, and pediatric/adult specialists
Awareness of ethnic variant clustering to inform genetic screening strategies
A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.
